Knight Therapeutics (TSE:GUD) Sets New 12-Month High – Here’s Why

Shares of Knight Therapeutics Inc. (TSE:GUD) hit a new 52-week high on Monday . The company traded as high as C$8.91 and last traded at C$8.88, with a volume of 33668 shares traded. The stock had previously closed at C$8.61.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group set a C$9.50 price objective on Knight Therapeutics and gave the stock a “buy” rating in a research report on Friday, May 8th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of C$9.50.

Knight Therapeutics Price Performance

The stock has a market capitalization of C$904.23 million, a P/E ratio of 153.50, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.14. The company has a current ratio of 2.32, a quick ratio of 1.79 and a debt-to-equity ratio of 8.86. The business has a fifty day simple moving average of C$7.88 and a 200 day simple moving average of C$6.72.

Knight Therapeutics (TSE:GUD) last announced its quarterly earnings data on Thursday, May 7th. The company reported C$0.13 earnings per share for the quarter. Knight Therapeutics had a return on equity of 0.73% and a net margin of 1.10%.The business had revenue of C$147.59 million during the quarter. On average, analysts expect that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current year.

About Knight Therapeutics

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.